Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Approved GSK’s Lamictal And Pfizer’s Genotropin Among Other Drugs

This article was originally published in PharmAsia News

Executive Summary

The first division on drugs of Ministry of Health, Labor and Welfare's Pharmaceutical Affairs and Food Sanitation Council approved July 25 GlaxoSmithKline's antiepileptic drug Lamictal (lamotrigine) to treat partial seizures in pediatric and adult patients with Lennox-Gastaut syndrome, Pfizer's human growth hormone Genotropin (somatropin), Novartis' Neoral (cyclosporine) to treat atopic dermatitis, Santan Pharmaceutical's tafluprost to treat galucoma and ocular hypertension, Aska Pharmaceutical's Menoaid Combipatch to treat menopausal symptoms and Schering-Plough's Bepricor (bepridil) to treat atrial fibrillation.(Click here for more - Japanese language) "First Section Of PAFSC Approves Epilepsy Drug Lamictal Among Other Drugs" - Yakuji News (7/29/08)

You may also be interested in...



Trump's Order For US Agencies To 'Buy American' Essential Medicines Has China Bracing For Impact

Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.

Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?

Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.

A More Perfect Meeting: Industry Seeks Additional PDUFA VII Metrics To Improve Communications

Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel